A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
← catalyst calendarSponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
427actual
Sites
53
Countries
Czechia, Estonia, Finland +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-03-30 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2020-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemophilia A
Intervention
- Drug: ELOCTA — also filed as ELOCTATE, efmoroctocog alfa, rFVIIIFc
Primary outcomes
what the primary-completion date above is the date OFJoint health: Target joint development
measured 48 months
Joint health: Target joint resolution
measured 48 months
Joint health: Target joint recurrence
measured 48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
measured 48 months
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed